ArticleThe Journal of clinical investigation2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review.Journal of translational medicine · 2025Pooled it
- Host metadherin coordinates hepatic lipid metabolism and CD8Cell metabolism · 2026Article
- Programmed cell death ligand 1 in correlation withFrontiers in immunology · 2026Article
- Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion.Cell research · 2026Article
- Citrullination in tumor immunity and therapy.The Journal of clinical investigation · 2025Review
- Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.Cell reports. Medicine · 2025Article
- Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements.Journal of translational medicine · 2025Review
- Ferroptosis contributes to immunosuppression.Frontiers of medicine · 2025Review
- Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype.Frontiers in immunology · 2025Review
- GPX4 knockdown suppresses M2 macrophage polarization in gastric cancer by modulating kynurenine metabolism.Theranostics · 2025Article
- HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.Frontiers in immunology · 2025Article
- Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.Biomolecules · 2024Review
- From foes to friends: rethinking the role of lymph nodes in prostate cancer.Nature reviews. Urology · 2024Review
- In vivo CRISPR screens identifyProceedings of the National Academy of Sciences of the United States of America · 2024Article
- [Advances of Fundamental Research on Traditional Chinese Medicine in Regulation of Tumor-associated Macrophages for the Prevention and Treatment of Lung Cancer Metastasis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma.Applied biochemistry and biotechnology · 2024Article
- Review
- An AI-based approach for modeling the synergy between radiotherapy and immunotherapy.Scientific reports · 2024Article
- PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages.Cell reports · 2024Article
- A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.International journal of molecular sciences · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum for
Authors and funding
19 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.